Denileukin Diftitox

證據等級: L5

預測適應症: 4 個

Denileukin Diftitox: From Cutaneous T-Cell Lymphoma to Metastatic Neoplasm

One-Sentence Summary

Denileukin diftitox (ONTAK) is a recombinant IL-2/diphtheria toxin fusion protein originally approved for cutaneous T-cell lymphoma (CTCL), targeting cells that express the high-affinity IL-2 receptor subunit CD25. The TxGNN model identifies Metastatic Neoplasm as the best-evidenced repurposing candidate (score: 99.01%), supported by 10+ clinical trials and 7 publications evaluating its use across metastatic melanoma, renal cell carcinoma, and other solid tumors. Evidence is rated at Level L2, driven primarily by completed Phase 2 trials in metastatic melanoma, yielding a “Proceed with Guardrails” recommendation for this indication.

Note on prediction ranking: The highest TxGNN-scored prediction is plasmacytoma (99.87%, rank #1), but it carries no supporting clinical or preclinical evidence (L5, Hold). Metastatic Neoplasm (99.01%, rank #4) is featured here as the clinically actionable prediction.

Quick Overview

Item	Content
Original Indication	Cutaneous T-cell lymphoma (CTCL)
Top TxGNN Prediction (by score)	Plasmacytoma — 99.87%, no supporting evidence (L5, Hold)
Best-Evidenced Prediction	Metastatic Neoplasm — 99.01%, L2 evidence
TxGNN Prediction Score	99.01% (Metastatic Neoplasm)
Evidence Level	L2
US Market Status	Not currently marketed
Number of NDAs	0
Recommended Decision	Proceed with Guardrails (Metastatic Neoplasm)

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current dataset. Based on known published information, denileukin diftitox is a recombinant fusion protein that couples the cytotoxic domain of diphtheria toxin to human IL-2. It binds to the high-affinity IL-2 receptor complex (CD25/CD122/CD132), which is expressed on malignant T-cells in CTCL as well as on immunosuppressive regulatory T cells (Tregs) broadly across tumor types. After receptor-mediated internalization, the diphtheria toxin moiety blocks protein synthesis and triggers cell death.

The repurposing rationale for metastatic neoplasm extends beyond the original CTCL target. In the tumor microenvironment (TME) of solid tumors such as melanoma and renal cell carcinoma, Tregs accumulate densely, suppress CD8+ effector T-cell activity, and express high levels of CD25. Denileukin diftitox can selectively deplete this Treg population, thereby reshaping the immunosuppressive TME and restoring endogenous anti-tumor immunity — or potentiating concurrently administered vaccines and immunotherapies. Multiple clinical trials have directly tested this hypothesis in patients with metastatic solid tumors.

The mechanistic concept has remained clinically relevant through successive generations: a next-generation reformulation (E7777/Lymphir, with higher purity and reduced immunogenicity) is now in active Phase 1/2 trials combined with pembrolizumab (NCT05200559, n=70), confirming that the CD25-targeting Treg-depletion strategy is a current focus of oncology drug development rather than an abandoned concept.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00299689	Phase 2	Completed	69	Denileukin diftitox (ONTAK) monotherapy in Stage IV metastatic melanoma; largest completed Phase 2 trial directly evaluating this agent as a standalone treatment for a metastatic solid tumor
NCT00082914	Phase 2	Completed	N/A	Direct evaluation of denileukin diftitox in metastatic melanoma or metastatic kidney cancer; tests ability to stimulate immune response to kill tumor cells in two major metastatic tumor subtypes
NCT00128622	Phase 1	Completed	24	Treg depletion with denileukin diftitox followed by CEA-expressing fowlpox-TRICOM dendritic cell vaccine in advanced or metastatic CEA-expressing malignancies; demonstrates feasibility of sequential Treg-depletion + vaccine strategy across multiple solid tumor types
NCT00278369	Early Phase 1	Completed	20	Denileukin diftitox combined with high-dose IL-2 in metastatic renal cell carcinoma; tests the hypothesis that Treg depletion can amplify IL-2-driven cytotoxic T-cell activity
NCT05200559	Phase 1/2	Recruiting	70	E7777 (next-generation denileukin diftitox reformulation) combined with pembrolizumab in recurrent or metastatic solid tumors including ovarian cancer; represents the current leading-edge development of this CD25-targeting mechanism
NCT00515528	Phase 2	Terminated	17	Randomized evaluation of multipeptide melanoma vaccine with or without denileukin diftitox in metastatic melanoma; terminated early, limiting interpretable outcomes
NCT02009384	Phase 2	Terminated	2	Ipilimumab administered after denileukin diftitox Treg depletion in Stage IIIC/IV melanoma; terminated due to very low enrollment
NCT00493129	Phase 2	Completed	8	ONTAK in systemic mastocytosis, a CD25-expressing mast cell malignancy; small sample limits generalizability but supports CD25-targeting rationale in non-lymphoma hematologic malignancies
NCT00726037	Phase 2	Terminated	7	Treg suppression by denileukin diftitox in metastatic pancreatic cancer to optimize timing of subsequent dendritic cell vaccination; terminated early, suggesting enrollment and feasibility challenges
NCT00945269	Phase 1/2	Terminated	3	Autologous CD8+ antigen-specific T cell clones infused after CD25-directed lymphodepletion in metastatic melanoma; early termination with minimal data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
16308572	2005	Clinical Trial	J Clin Invest	Denileukin diftitox selectively eliminates CD25+ Tregs from cancer patient PBMCs without toxicity to CD25-intermediate/low populations; Treg depletion significantly enhances immunostimulatory efficacy of tumor RNA-transfected DC vaccines — foundational mechanistic evidence
18334033	2008	Clinical Research	J Transl Med	Transient Treg depletion with denileukin diftitox induced regression of melanoma metastases in patients; provides direct in-human evidence that Treg removal can break tumor immune tolerance and produce anti-tumor responses
20664355	2010	Phase 1 Trial	J Immunother	Denileukin diftitox + high-dose IL-2 in metastatic renal cell carcinoma; sequential Treg depletion followed by cytokine immunotherapy explored to overcome Treg-mediated suppression and improve IL-2 response rates
16224276	2005	Clinical/Mechanistic	J Immunother	At standard doses, denileukin diftitox did not reliably eliminate Tregs in melanoma patients; important cautionary finding raising questions about optimal dosing, scheduling, and Treg CD25 expression variability
21770473	2011	Review	Drugs	Review of novel immunotherapeutic approaches for metastatic melanoma; includes denileukin diftitox among Treg-targeting strategies alongside ipilimumab, placing it in the evolving immunotherapy landscape
18410797	2008	Review	Semin Oncol	Review of emerging agents for anthracycline- and taxane-refractory metastatic breast cancer; denileukin diftitox mentioned as a candidate in the broader context of metastatic solid tumor immunotherapy
21990092	2011	Review/Guideline	Am J Hematol	CTCL 2011 diagnostic and management update; provides reference context for denileukin diftitox’s original FDA-approved indication and its established role prior to market withdrawal

US Market Information

Denileukin diftitox is not currently listed as an active product in the US regulatory database under DrugBank ID DB00004. The original formulation (ONTAK, Eisai) received FDA approval for CTCL but was withdrawn from the US market in 2014 primarily due to manufacturing concerns. A next-generation, higher-purity reformulation — E7777, commercially known as Lymphir — received FDA approval in August 2023 for CTCL under a separate regulatory filing and is currently marketed.

No active NDA entries are available for this drug compound entry.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy / Immunotoxin — recombinant IL-2 receptor–directed diphtheria toxin conjugate; not conventional cytotoxic chemotherapy
Myelosuppression Risk	Moderate — intended lymphodepletion (Treg and CD25+ lymphocyte depletion) is the primary pharmacological mechanism; monitor for broader lymphopenia
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential, lymphocyte subsets (CD4, CD8, Treg/CD25+), serum albumin (vascular leak syndrome surveillance), liver transaminases, creatinine, and fluid balance
Handling Protection	As a biologic immunotoxin, handle according to institutional cytotoxic biologic protocols; cold-chain storage required; avoid exposure via needlestick or mucosal contact

Safety Considerations

Please refer to the package insert for complete safety information, as specific warning and contraindication data were not available in the current dataset.

Critical known risk: Denileukin diftitox carries a well-documented risk of vascular leak syndrome (capillary leak syndrome), characterized by hypoalbuminemia, edema, and hypotension. This was a significant clinical concern during the ONTAK era and must be proactively addressed in any new trial design or compassionate-use protocol.

Conclusion and Next Steps

Decision: Proceed with Guardrails (for Metastatic Neoplasm indication)

Rationale: Two completed Phase 2 trials directly evaluate denileukin diftitox in metastatic solid tumors — including one with n=69 in metastatic melanoma (NCT00299689) — and multiple Phase 1 trials confirm mechanistic feasibility of Treg depletion across tumor types. The ongoing Phase 1/2 trial of the next-generation formulation (E7777 + pembrolizumab, n=70) demonstrates continued industry investment in this mechanism, lowering the de-risking burden for a repurposing program.

To proceed, the following is needed:

Full mechanism of action documentation from DrugBank API (currently a data gap)
US FDA label review — use the Lymphir (E7777) label as the most current reference for safety warnings, dosing, and vascular leak syndrome management guidelines
Biomarker-driven patient selection strategy: prospective assessment of tumor CD25 expression and Treg density as enrollment criteria
Vascular leak syndrome risk mitigation protocol embedded in any new clinical trial design
Evaluation of combination strategy (e.g., with anti-PD-1/PD-L1 checkpoint inhibitors), given that NCT05200559 is already testing this approach with the next-generation analog
Regulatory pathway clarification: whether to pursue denileukin diftitox (DB00004) directly or position this as foundational evidence for the E7777 (Lymphir) repurposing program
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.